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Results: Sequencing results of the tumours in the first three 
analysed patients showed somatic alterations of the cell 
cycle (TP53, CDKN2B), PI3K; AKT; RAS signaling cascades 
(ERBB3, HRAS, VHL, MTOR), chromatin regulation (TET2, 
ARID1A, KMT2A, EZH2, MEN1), Notch signaling (FBXW7, 
NOTCH1) and DNA damage response (BRCA1/2, MLH1). The 
amount of cfDNA varied among patients and during 
treatment. Quantitatively, in 5 patients the amount of cfDNA 
increased during therapy (after week 1). In 4 patients no 
initial relevant change could be seen (stable after week 1). 
Currently patients are in follow up for evaluation of clinical 
outcome. 
 
Conclusion: Our initial results suggest that monitoring cfDNA 
identifies different patient subsets. As a proof of concept, 
detection of cfDNA is feasible and a potentially promising 
tool to identify tumour specific ‘finger prints’. Perspectively 
we hope to use cfDNA as a liquid biopsy and biomarker to 
identify individual tumour signatures to personalise 
treatments, detect mutations for targeted therapies and to 
monitor treatment response. 
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Purpose or Objective: To evaluate the clinical outomes to 
find optimal treatment and analyze prognostic factors for 
squamous cell carcinoma of maxillary sinus. 
 
Material and Methods: Between January 1990 and December 
2014, 97 patients with histoligcally proven squamous cell 
carcinoma of maxillary sinus without distant metastasis, 
treated with either radical surgery and adjuvant 
radiotherapy(Op+RT) or radical radiotherapy(RT). Median age 
at diangnosis was 61. There was no stage I patient and only 5 
patients were stage II, all treated with Op+RT. Among 
twenty-three patients with stage III disease, fifteen patients 
were treated with Op+RT and eight patients were treated 
with RT. For stage IVA cancer, thirty-three patients received 
Op+RT, and twenty-eight patients were treated with RT. All 
eight patients with stage IVB cancer were treated with RT. 
Neoadjuvant chemotherapy and concurrent chemotherapy 
were used in fourty-five and nineteen patients, respectively. 
 
Results: Median follow-up period after diagnosis was 30 
months for all patients. For stage III cancer, Op+RT showed 
better outcomes than RT (5-year OS : 63.8% vs. 29.2%, 
p=0.12; 5-year PFS : 43.2% vs. 18.8%, p=0.16), although not 
statistically significant. For stage IVA cancer, however, two 
treatment options showed comparable results (5-year OS : 
52.6% vs. 51.3%, p=0.80; 5-year PFS : 37.6% vs. 28.6%, 
p=0.53). Local failure was the most common pattern of 
failure, found in fourty-two of ninty-seven patients (43.3%). 
Proportion of regional failures in initially node-positive 
patients was 21.4% (three out of fourteen). For initially node-
negative cancer, regional failure was not observed in fifteen 
patients who received either neck dissection or neck 
irradiation, but in 14.7% (ten out of sixty-eight) who did not 
received neck treatment. In multivariate analysis, age 
younger than 60, positive resection margin and masticator 
space invasion were bad prognostic factors in Op+RT group. 
Masticator space invasion and subcutaneous tissue of cheek 
invasion were bad prognostic factors in RT group. 
 
Conclusion: In squamous cell carcinoma of maxillary sinus, 
radical surgery followed by adjuvant radiotherapy should be 
recommended for stage III disease. For stage IVA, however, 
radical radiotherapy can be a good alternative option to 
surgery. Prophylactic neck treatment for initially node 
negative patients can prevent regional recurrence, with 
absolute risk reduction of about 15%. Masticator space 
invasion was found to be a bad prognostic factor for both 
treatment arms. 
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Purpose or Objective: Due to a risk of 18 to 45% of occult 
nodal metastases in cN0 HNSCC patients, prophylactic neck 
irradiation is often mandatory. Anyway, it leads to a large 
irradiation of normal tissues because bilateral drainage is the 
rule in only 30 to 50 % of individuals. Moreover, 15 to 30 % of 
the tumors drain in unpredicted nodal basins (risk of 
geographical miss). SPECT/CT lymphoscintigraphy of sentinel 
lymph nodes (SLN) could help individualizing prophylactic 
irradiation levels in cN0 patients and, hence, reduce 
irradiated volume and improve quality of life (QoL). This 
ongoing prospective phase II study investigates its oncological 
safety.  
 
Material and Methods: Twenty-six patients with newly 
diagnosed cN0 SCC of the oral cavity, oropharynx, larynx or 
hypopharynx were included. All patients were imaged with 
SPECT/CT after 99mTc nanocolloid injection around the 
tumor. The neck levels containing up to four hottest SLN 
were identified and selected for prophylactic irradiation 
(CTVn-LS) by volumetric modulated arc therapy. A 
comparative virtual planning was performed with volumes 
selected according to international guidelines (CTVn-IG). QoL 
was assessed using EORTC C30 and HN25 scales. 
 
Results: Migration was observed in all of the 26 patients (one 
with gamma probe only) with an average of 2.8 sentinel 
nodes detected per patient. CTVn-LS was totally 
encompassed by CTVn-IG in all patients but two with an 
unpredicted drainage in homolateral retropharyngeal levels. 
More than half of the patients has only a unilateral drainage. 
CTVn-LS and related PTV were systematically smaller than IG 
ones, by a factor of two on average. This led to significant 
dose decrease in identified OAR as well as remaining volume 
at risk. With a median follow-up of 24 months, no regional 
relapse was observed while 3 patients had a local one (11%). 
Crude overall survival rate is 89%. QoL preliminary data will 
be presented. 
 
Conclusion: SPECT/CT lymphoscintigraphy of SLN allows 
individualizing prophylactic node CTV in cN0 HNSCC patients 
eligible for definitive radiotherapy. Both CTV and PTV are 
significantly reduced, which results in a significant dose 
decrease in OAR. At a median follow-up of 24 months, no 
regional relapse was observed but further follow-up and 
recruitment are necessary to ensure the oncological safety. 
QoL data are being analyzed. 
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Purpose or Objective: The aim of this study is to identify 
prognostic factors of treatment related toxicity after 
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concomitant radiochemotherapy in patients affected by head 
and neck cancer. 
 
Material and Methods: 226 patients, 38 female and 188 
male, with head and neck cancer, treated with 
chemoradiotherapy from 1995 to 2014 at our department, 
were retrospectively reviewed. 59,7% of patients were 
younger than 60 years. The anatomical sites of cancer were: 
36 nasopharynx, 63 oropharynx, 34 oral cavity, 51 larynx, 26 
hypopharynx, 16 others sites. 64 patients underwent to post-
operative treatment and 162 to radical treatment. They were 
treated with 2D-3DCRT (80%) or IMRT technique (20%). The 
mean dose administered was 68 Gy (range 60-74). The 
schedule of chemotherapy most used included cisplatin and 
5-FU. Acute and late toxicity are assessed according to 
CTCAE v.4.0 scale. Age, gender, tumor/nodal stage, primary 
site, tumor grading, RT technique and dose were assessed as 
potential prognostic factors influencing treatment toxicity. 
 
Results: Acute dysphagia and mucositis G2-3 were observed 
in 82,7% and 84,9% respectively of patients and were related 
with young age (p=0,03 and p=0,02), pharynx site (p=0,004 
and p<0,003) and advanced stage (p=0,02 and p=0,009). 
Acute xerostomia G2-3 (15%) was associated with 
oropharyngeal and oral cavity sites (p=0,03) and RT technique 
(p=0,004). Late xerostomia G2-3 (25,2%) was related with 
oropharyngeal site (p=0,04) and late fibrosis (14,1%) with 
nodal stage (p=0,005). Acute and late hearing loss (4,8%) was 
observed more frequently in nasopharyngeal cancer (p=0,03 
and p=0,001 respectively). 3,5% of patients had acute 
neurotoxicity and 4,8% late neurotoxicity; this adverse effect 
was associated with nasopharyngeal site (p=0,03 and p=0,03 
respectively). 
 
 
 
Conclusion: Clinical and technical data may be predictive of 
severe toxicity. Younger patients with pharynx cancer are 
more susceptible to dysphagia, mucositis and xerostomia. In 
this subset of patients it's critical evaluate strategies of 
adaptive radiotherapy with the aim to decrease the toxicity. 
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Purpose or Objective: To analyze clinical outcome and 
prognostic factors in a consecutive series of 160 non-
metastatic nasopharyngeal carcinoma (NPC) patients (pts) 
treated curatively with intensity modulated radiotherapy 
(RT) techniques (IMRT, Intensity Modulated Radiation Therapy 
or VMAT, Volumetric Modulated Arc Therapy) and 
chemotherapy (CT). 
 
Material and Methods: Pts were treated between October 
2004 and April 2014 at our institution. Median age at 
diagnosis was 49 years (range 18-92). According to WHO, 144 
patients (90%) were suffering from undifferentiated NPC, 5 
patients (3.1%), 3 patients (1.9%) and 8 patients (5%) were 
respectively affected by squamous cell carcinoma G1, G2 or 
G3. One pt was in stage I (0.6%), 31 pts (19.4%) were in stage 
II, 47 pts (29.4%) in stage III, 31 pts (19.4%) in stage IVA and 
50 pts (31.2%) in stage IVB. Seven pts (4.4%) received RT 
alone: 1 pt in stage I and 6 pts in stage II. Of the remaining 
153 pts (95.6%) (25 pts with stage II and 128 pts with stage III 
and IV) 34 patients (21.2%) received CT concomitant to RT 
and 119 patients (74.4%) were treated with induction CT 
followed by RT-CT. IMRT was given with standard 
fractionation at a total dose of 70 Gy. In 134 patients 
(83.75%) circulating plasma EBV-DNA has been measured 
before treatment using quantitative PCR. A dedicated 
software (VODCA, www.vodca.ch) was used to collect and 
analyze dosimetric parameters in 137 pts. 
 
Results: With a median follow up of 55.7 months (range 3.8 - 
118.7) actuarial rates at 2 and 5 years were respectively: 
overall survival (OS) 92.36% and 82.81%, disease-free survival 
(DFS) 83.1% and 77.2%, local control (LC) 92.17% and 90.43%, 
locoregional control (LRC) 94.78% and 93.04% and distant 
control (DC) 89.57% and 86.96%. At univariate analysis N 
stage (N0+N1+N2+N3a vs N3b) was found to be a prognostic 
factor for DM (p = 0.029). At multivariate analysis conducted 
on the following parameters: T stage, N stage, stage, RT 
technique , V95%, Dmean and D99% (relative to High Risk 
PTV), the stage of T (T1+T2+T3 vs T4) was found to be a 
prognostic factor for LRC (p = 0.035). Both at univariate and 
multivariate analysis the stage of T was found to be a 
prognostic factor for LC (p = 0.004 and .011 respectively) and 
N stage (N0+N1+N2 vs N3) for DM and RC. Pts with a V95% > 
90% had better LC (p=0.004) and DFS (p=0.047). Pts with a 
Dmean > 69 Gy had better LC (p=0.029). Pts with a D99% > 64 
Gy had better LC (p=0.008) and OS (p=0.004). The threshold 
value of 45 cc of GTV T (Gross Tumor Volume of the primary 
tumor) was prognostic for LC (p = 0.0095). The threshold 
value of 1500 copies of EBV-DNA was prognostic for DC (p = 
0.048). 
 
Conclusion: The intensified treatment of CT-IMRT / VMAT 
achieves excellent clinical outcomes. Besides traditional 
prognostic factors, we demonstrated the prognostic value of 
dosimetric parameters. Finally, for the first time in a non-
endemic area threshold values of GTV T and EBV-DNA 
prognostic for LC and DC respectively have been confirmed. 
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Purpose or Objective: Technological advances have enabled 
clinicians to explore dose escalation strategies in various 
tumor sites. Intermediate and high risk oropharyngeal 
cancers have unsatisfactory 3 year outcomes. The 
simultaneous integrated boost (SIB) technique with dose per 
fraction slightly higher than 2Gy offers the advantages of 
shortening the treatment time and increasing the biologically 
equivalent dose to the tumor. This retrospective study is 
aimed to evaluate the clinical outcome of radiation dose 
escalation to 18FDG PET/CT positive tumor and nodal sub 
volumes using the Simultaneous Integrated Boost (SIB) IMRT 
technique by means of Helical Tomotherapy (HT) in locally 
advanced Oropharyngeal cancer patients (pts). 
 
Material and Methods: 37 pts, median age 59 years (range: 
41-81), treated between 2005 and 2014, were evaluated. 
Reported stage were III-IVAB (4 and 33 respectively). HT was 
delivered with the SIB technique at different dose levels: 
69Gy (2.3 Gy/day) to the PET-positive volume (GTV-PET), 66 
